お知らせ :東京証券取引所JASDAQスタンダード市場への新規上場に関するお知らせ
株式会社グローバルインフォメーション
表紙:緑内障:パイプライン分析
市場調査レポート
商品コード
232844

緑内障:パイプライン分析

Glaucoma - Pipeline Review, H2 2020

出版日: | 発行: Global Markets Direct | ページ情報: 英文 385 Pages | 納期: 即納可能 即納可能とは

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=111.11円
緑内障:パイプライン分析
出版日: 2020年09月30日
発行: Global Markets Direct
ページ情報: 英文 385 Pages
納期: 即納可能 即納可能とは
担当者のコメント
本レポートは最新情報反映のため適宜更新し、内容構成変更を行う場合があります。ご検討の際はお問い合わせください。
  • 全表示
  • 概要
  • 図表
  • 目次
概要

緑内障は、眼球内の液圧が上昇する眼の病気です。緑内障による視神経障害の正確な原因は完全には解明されていませんが、視神経の機械的圧迫および/または血流低下が関与しています。徴候および症状には、目の痛み、吐き気および嘔吐(激しい目の痛みを伴う)、視力障害の突然の発症、しばしば微光下での視力のぼやけおよび目の発赤が含まれます。

当レポートでは、緑内障の治療薬開発パイプラインの現況と最新アップデートによる各開発段階の比較分析、企業や研究機関によって開発中の治療薬、治療薬の評価、後期段階および中止されたプロジェクトに関する情報などを最新のニュースや発表も交えて提供しています。

イントロダクション

緑内障の概要

緑内障:治療薬の開発

緑内障:治療薬の評価

緑内障の治療薬開発に従事している企業

薬剤プロファイル

緑内障:休止中のプロジェクト

緑内障:開発が中止された製品

緑内障:最近のパイプライン動向

緑内障:製品開発のマイルストーン

付録

図表

List of Tables

List of Tables

  • Number of Products under Development for Glaucoma, H2 2020
  • Number of Products under Development by Companies, H2 2020
  • Number of Products under Development by Universities/Institutes, H2 2020
  • Products under Development by Companies, H2 2020
  • Products under Development by Universities/Institutes, H2 2020
  • Number of Products by Stage and Target, H2 2020
  • Number of Products by Stage and Mechanism of Action, H2 2020
  • Number of Products by Stage and Route of Administration, H2 2020
  • Number of Products by Stage and Molecule Type, H2 2020
  • Glaucoma - Pipeline by AbbVie Inc, H2 2020
  • Glaucoma - Pipeline by AC Immune SA, H2 2020
  • Glaucoma - Pipeline by Aerie Pharmaceuticals Inc, H2 2020
  • Glaucoma - Pipeline by Aerpio Pharmaceuticals Inc, H2 2020
  • Glaucoma - Pipeline by Allergan Ltd, H2 2020
  • Glaucoma - Pipeline by Amgen Inc, H2 2020
  • Glaucoma - Pipeline by Annexon Inc, H2 2020
  • Glaucoma - Pipeline by Annovis Bio Inc, H2 2020
  • Glaucoma - Pipeline by Asha Vision LLC, H2 2020
  • Glaucoma - Pipeline by Betaliq Inc, H2 2020
  • Glaucoma - Pipeline by Better Life Pharmaceuticals Inc, H2 2020
  • Glaucoma - Pipeline by Bial - Portela & Ca SA, H2 2020
  • Glaucoma - Pipeline by BioAxone BioSciences Inc, H2 2020
  • Glaucoma - Dormant Projects, H2 2020
  • Glaucoma - Discontinued Products, H2 2020

List of Figures

List of Figures

  • Number of Products under Development for Glaucoma, H2 2020
  • Number of Products under Development by Companies, H2 2020
  • Number of Products under Development by Universities/Institutes, H2 2020
  • Number of Products by Top 10 Targets, H2 2020
  • Number of Products by Stage and Top 10 Targets, H2 2020
  • Number of Products by Top 10 Mechanism of Actions, H2 2020
  • Number of Products by Stage and Top 10 Mechanism of Actions, H2 2020
  • Number of Products by Top 10 Routes of Administration, H2 2020
  • Number of Products by Stage and Top 10 Routes of Administration, H2 2020
  • Number of Products by Top 10 Molecule Types, H2 2020
  • Number of Products by Stage and Top 10 Molecule Types, H2 2020
目次
Product Code: GMDHC12579IDB

Summary:

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Glaucoma - Pipeline Review, H2 2020, provides an overview of the Glaucoma (Ophthalmology) pipeline landscape.

Glaucoma is a disease of the eye in which fluid pressure within the eye rises. The exact cause of optic nerve damage from glaucoma is not fully understood, but involves mechanical compression and/or decreased blood flow of the optic nerve. The most important risk factors include age, elevated eye pressure, African ancestry, thin cornea, family history of glaucoma. Signs and symptoms include eye pain, nausea and vomiting (accompanying the severe eye pain), sudden onset of visual disturbance, often in low light, blurred vision and reddening of the eye.

Report Highlights:

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Glaucoma - Pipeline Review, H2 2020, provides comprehensive information on the therapeutics under development for Glaucoma (Ophthalmology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Glaucoma (Ophthalmology) pipeline guide also reviews of key players involved in therapeutic development for Glaucoma and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 3, 14, 18, 12, 4, 70, 19 and 5 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 13 and 3 molecules, respectively.

Glaucoma (Ophthalmology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Glaucoma (Ophthalmology).
  • The pipeline guide reviews pipeline therapeutics for Glaucoma (Ophthalmology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Glaucoma (Ophthalmology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Glaucoma (Ophthalmology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Glaucoma (Ophthalmology)

Reasons to Buy:

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Glaucoma (Ophthalmology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Glaucoma (Ophthalmology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

Table of Contents

  • Introduction
  • Glaucoma - Overview
  • Glaucoma - Therapeutics Development
  • Glaucoma - Therapeutics Assessment
  • Glaucoma - Companies Involved in Therapeutics Development
  • Glaucoma - Drug Profiles
  • Glaucoma - Dormant Projects
  • Glaucoma - Discontinued Products
  • Glaucoma - Product Development Milestones
  • Appendix
株式会社グローバルインフォメーション
© Copyright 1996-2021, Global Information, Inc. All rights reserved.